With Biotech IPOs Back in the Works, We've Even Stopped Worrying About the Housing Market

Oct 26, 2007

David Hamilton at VentureBeat has an article on XDx, a molecular diagnostic company focusing on gene expression tests, which just filed for an IPO to raise as much as $87 million. The article lays out the case for gene-expression-based diagnostics, but also notes that so far these tests have "been slow to catch on." The article runs through similar existing tests, and gives a nice snapshot of the XDx business.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Changes to the Lancet's Process

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

Emails Show Pressure on CDC

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

Into One System

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

PLOS Papers on Dilated Cardiomyopathy, Lung Cancer Epigenetics, Pediatric Staphylococcus aureus Infections

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.

Menu